Øivind Torkildsen is professor of neurology, Head of Section for Neurology at the University of Bergen, Norway and consultant neurologist at the Department of Neurology, Haukeland Univiersity Hospital, Norway. He has a long research experience in both clinical and preclinical studies.  He is the principal investigator and national coordinator of both industry- and investigator initiated studies, and he has since 2004 conducted a number of clinical trials in multiple sclerosis.  

His current research focuses on the etiology of the disease and on discovering new therapeutic options against multiple sclerosis. 

He is a member of the Norwegian Medical Association, the Norwegian Neurological Association and Fellow of European Academy of Neurology (FEAN). He is coordinating the EBV-MS project financed by the Horizon 2023 EU grant (Overview of all EBV-MS project partners | EBV-MS | UiB).

Academic article

• Lisa G. Schoof; Brit Ellen Rød; Sahla El Mahdaoui et al. (2025). Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysis. (external link)
• Jeremy Hobart; Amy Bowen; George Pepper et al. (2018). International consensus on quality standards for brain health-focused care in multiple sclerosis. (external link)
• Trygve Holmøy; Qin Ying Esbensen; Øivind Torkildsen et al. (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study.. (external link)
• Frank Riemer; Ellen Skorve; Ofer Pasternak et al. (2023). Microstructural changes precede depression in patients with relapsing-remitting Multiple Sclerosis. (external link)
• Øivind Fredvik Torkildsen; Christian A. Vedeler; Elling Ulvestad et al. (2005). High dose methylprednisolone induces FcgammaR1 on granulocytes in MS-patients. (external link)
• O Torkildsen; Øivind Fredvik Torkildsen; Egil Utsi et al. (2005). Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. (external link)
• Eystein Oveland; Agnes Elisabeth Nystad; Frode Berven et al. (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. (external link)
• Ann Cathrine Kroksveen; Jacob D. Jaffe; Elise Aasebø et al. (2015). Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. (external link)
• Øivind Torkildsen; Øystein Alexander Power; Anette Storstein (2016). Detection of varicella-zoster virus DNA during medullary and brainstem relapses in multiple sclerosis. (external link)
• Brage Brakedal; Irene Hana Flønes; Simone B. C. Frizell Reiter et al. (2017). Glitazone use associated with reduced risk of Parkinson's disease. (external link)
• Øivind Torkildsen; Kjell-Morten Myhr; Lars Bø (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. (external link)
• Brit Ellen Rød; Einar August Høgestøl; Øivind Torkildsen et al. (2025). Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation. (external link)
• Jette Lautrup Frederiksen; Luca Massacesi; Helle Hvilsted Nielsen et al. (2024). Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study. (external link)
• Øivind Fredvik Grytten Torkildsen; Alla Nikolajevna S Bru; Gry Inger N Behzadi et al. (2026). Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. (external link)
• Ragnhild Reehorst Lereim; Eystein Oveland; Y. Xiao et al. (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. (external link)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2019). Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. (external link)
• Øivind Fredvik Torkildsen; Per Knappskog; Harald Inge Nyland et al. (2008). Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. (external link)
• Ellen Skorve; Astri Lundervold; Øivind Torkildsen et al. (2019). The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS). (external link)
• Sveinung Fjær; Lars Bø; Kjell-Morten Myhr et al. (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. (external link)
• Tomas Kalincik; Sifat Sharmin; Izanne Roos et al. (2024). Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. (external link)
• Øivind Torkildsen; Kristin Ingeleiv Løken-Amsrud; Stig Wergeland et al. (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. (external link)
• Jens Kuhle; G Disanto; R Dobson et al. (2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study. (external link)
• Grethe Åstrøm Ueland; Hans Olav Ueland; Ann-Elin Meling Stokland et al. (2023). Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease. (external link)
• Øivind Fredvik Torkildsen; Harald Inge Nyland; Helge Myrmel et al. (2008). Epstein-Barr virus reactivation and multiple sclerosis. (external link)
• E. Coerver; L. Schoof; L. Hogenboom et al. (2024). The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. (external link)
• Sveinung Fjær; Lars Bø; Arvid Lundervold et al. (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. (external link)
• Silje Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2016). No association of tobacco use and disease activity in multiple sclerosis. (external link)
• Stig Wergeland; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. (external link)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. (external link)
• Brit Ellen Rød; Øivind Torkildsen; Kjell-Morten Myhr et al. (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. (external link)
• Øivind Fredvik Torkildsen; Linn Anne Brunborg; Anne Marita Milde et al. (2009). A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. (external link)
• Ingrid Anne Lie; Kristin Wesnes; Silje Agnethe Stokke Kvistad et al. (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. (external link)
• Kjell-Morten Myhr; Nina Agnethe Grytten; Øivind Torkildsen et al. (2012). A need for national registries and international collaborative research in multiple sclerosis. (external link)
• Liv Furevik; Oksana Lapina; Elisabeth Margrete Stokke Lindland et al. (2025). Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study. (external link)
• Trygve Holmøy; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. (external link)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2024). Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women. (external link)
• Yichuan Xiao; Jin Jin; Mikyoung Chang et al. (2013). Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. (external link)
• Kristin Nielsen Varhaug; Christian Barro; Kjetil Lauvland Bjørnevik et al. (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. (external link)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). The cuprizone model: regional heterogeneity of pathology. (external link)
• Øivind Fredvik Torkildsen; Jan Harald Aarseth; Espen Benjaminsen et al. (2014). Month of birth and risk of multiple sclerosis: confounding and adjustments. (external link)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. (external link)
• Agnes Elisabeth Nystad; Stig Wergeland; Lage Aksnes et al. (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. (external link)
• Øivind Fredvik Torkildsen; Linn Anne Brunborg; Frits Alan Thorsen et al. (2009). Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. (external link)
• Stig Wergeland; Anagha P Parkar; Snezana Maric et al. (2021). En ung kvinne med langvarig kvalme, oppkast og hikke. (external link)
• Hilde Marie Torgauten; Therese Bredholt Onyango; Sonja Ljostveit et al. (2024). Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. (external link)
• Kjetil Lauvland Bjørnevik; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.. (external link)
• Agnes Elisabeth Nystad; Ragnhild Reehorst Lereim; Stig Wergeland et al. (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. (external link)
• Trond Trætteberg Serkland; Silje Skrede; Erik Ingmar Hallin et al. (2025). Pharmacokinetic-pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval. (external link)
• Hilde Marie Torgauten; Kjell-Morten Myhr; Stig Wergeland et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. (external link)
• Maria Ban; Stacy Caillier; Inger-Lise Mero et al. (2013). No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. (external link)
• Margitta Theodora Kampman; Jan Harald Aarseth; Nina Agnethe Grytten et al. (2013). Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. (external link)
• Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Kjell-Morten Myhr et al. (2008). The cuprizone model for demyelination. (external link)
• Maria Therese Fossum; Hilde Marie Torgauten; Jan Harald Aarseth et al. (2025). Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety. (external link)
• Silje Agnethe Stokke; Anne Kristine Lehmann; Linn Trovik et al. (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. (external link)
• Ingrid Anne Lie; Sezgi Kacar; Kristin Wesnes et al. (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. (external link)
• Ellen Skorve; Astri Lundervold; Øivind Torkildsen et al. (2020). A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS. (external link)
• Øivind Fredvik Torkildsen; Christine Stansberg; Solveig Mjelstad Angelskår et al. (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. (external link)
• Trygve Holmøy; Øivind Torkildsen; Kjell-Morten Myhr (2017). An update on cladribine for relapsing-remitting multiple sclerosis. (external link)
• Shamundeeswari Anandan; Karina Maciak; Regina Breinbauer et al. (2025). In-Depth Characterization of L1CAM+ Extracellular Vesicles as Potential Biomarkers for Anti-CD20 Therapy Response in Relapsing–Remitting Multiple Sclerosis. (external link)
• Max Korbmacher; Ingrid Anne Lie; Kristin Wesnes et al. (2025). Multimodal predictors of disability progression and processing speed decline in relapsing–remitting multiple sclerosis. (external link)
• Øivind Torkildsen; Nina Agnethe Grytten; Jan Harald Aarseth et al. (2012). Month of birth as a risk factor for multiple sclerosis: an update. (external link)
• Kristin Ingeleiv Løken; Kjell-Morten Myhr; Jacob Bakke et al. (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. (external link)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2021). Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study. (external link)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. (external link)
• Katharina Natalie Gottschlich; Zinajda Zolic-Karlsson; Eline Aas et al. (2024). Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis. (external link)
• Karine Eid; Øivind Fredvik Grytten Torkildsen; Jan Harald Aarseth et al. (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. (external link)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Association of adverse childhood experiences with the development of multiple sclerosis. (external link)
• Christopher Elnan Kvistad; Øivind Torkildsen; Halvor Næss et al. (2016). Trombolytisk behandling og trombektomi ved ukjent slagdebut. (external link)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. (external link)
• Egil Rørvik Røsjø; Peter Andreas Vold Lossius; Nada Abdelmagid et al. (2017). Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. (external link)
• Jan-Lukas Førde; Lars Herfindal; Kjell-Morten Myhr et al. (2023). Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro. (external link)
• Jill Anette Opsahl; Marc Vaudel; Astrid Guldbrandsen et al. (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. (external link)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. (external link)
• Brit Ellen Rød; Stig Wergeland; Kjetil Lauvland Bjørnevik et al. (2023). Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. (external link)
• Kjell-Morten Myhr; Øivind Fredvik Torkildsen (2020). Serum NFL levels should be used to monitor multiple sclerosis evolution - No.. (external link)
• Kristin Ingeleiv Løken-Amsrud; Peter Andreas Vold Lossius; Øivind Torkildsen et al. (2015). Miljøets betydning ved multippel sklerose. (external link)
• Christopher Elnan Kvistad; Anne Kristine Lehmann; Silje Agnethe Stokke et al. (2024). Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway. (external link)
• Øivind Fredvik Torkildsen; Kjell-Morten Myhr; Vegard Skogen et al. (2020). Tenofovir as a treatment option for multiple sclerosis. (external link)
• Tomas Kalincik; Sifat Sharmin; Izanne Roos et al. (2023). Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. (external link)
• Nina Agnethe Grytten; Øivind Torkildsen; Jan Harald Aarseth et al. (2013). Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. (external link)
• Kjetil Bjørnevik; Trond Riise; Espen Benjaminsen et al. (2017). Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. (external link)
• Ann Cathrine Kroksveen; Astrid Guldbrandsen; Marc Vaudel et al. (2017). In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. (external link)
• Hanne Marie Lunde; Øivind Torkildsen; Lars Bø et al. (2016). Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. (external link)
• Ann Cathrine Kroksveen; Jill Anette Opsahl; Astrid Guldbrandsen et al. (2015). Cerebrospinal fluid proteomics in multiple sclerosis. (external link)
• Kristin Wesnes; Kjell-Morten Myhr; Trond Riise et al. (2021). Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. (external link)
• Trygve Holmøy; Øivind Torkildsen (2016). Familieplanlegging, graviditet og amming ved multippel sklerose. (external link)
• Silje Agnethe Stokke; Joachim Burman; Anne Kristine Lehmann et al. (2022). Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. (external link)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2018). Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. (external link)
• Agnes Elisabeth Nystad; Øivind Torkildsen; Stig Wergeland (2018). Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. (external link)
• O Torkildsen; Øivind Fredvik Torkildsen; Egil Utsi et al. (2005). Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. (external link)
• Sonia Gavasso; Øivind Torkildsen; Tove Helene Marøy et al. (2012). Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. (external link)
• Øivind Fredvik Torkildsen; Christian A. Vedeler; Harald Inge Nyland et al. (2006). Fc gamma R and multiple sclerosis: an overview. (external link)
• Rune Alexander Høglund; Haakon Eduard Meyer; Hein Stigum et al. (2021). Association of body mass index in Adolescence and young Adulthood and long-term risk of multiple Sclerosis: A Population-Based Study. (external link)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. (external link)
• Øivind Torkildsen; Kjell-Morten Myhr; Stig Wergeland (2014). Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. (external link)
• Øivind Torkildsen (2022). Hva vi kan lære av historien om lobotomi. (external link)
• Anne Lise Karlsgot Hestvik; Jette Lautrup Frederiksen; Helle Hvilsted Nielsen et al. (2022). Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes. (external link)
• Andrea Kyvik Habbestad; Johannes Sverre Willumsen; Jan Harald Aarseth et al. (2023). Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. (external link)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2025). High-dimensional Immune Profiling Following Autologous Hematopoietic Stem Cell Transplantation in Relapsing-Remitting Multiple Sclerosis. (external link)
• Maria Nordheim Alme; Agnes Elisabeth Nystad; Lars Bø et al. (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. (external link)
• Øivind Torkildsen; Stig Wergeland; Jacob Bakke et al. (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. (external link)
• Øivind Torkildsen; Elisabeth Farbu (2005). Lars Hertervig og Carl Fredrik Hill - kreativitet og psykisk sykdom. (external link)
• Sedina Atic Kvalvik; Ingerid Skarstein; Anne Veddeng et al. (2020). An immunocompromised woman in her twenties with abdominal pain and vaginal discharge. (external link)
• Ingrid Anne Lie; Emma Kerklingh; Kristin Wesnes et al. (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. (external link)
• Egil Rørvik Røsjø; Linn Hofsøy Steffensen; Lone Jørgensen et al. (2015). Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. (external link)
• Egil Rørvik Røsjø; Jonas Christoffer Lindstrøm; Trygve Holmøy et al. (2020). Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. (external link)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2022). Cancer related mortality in multiple sclerosis. A population based cohort study. (external link)
• Kristin Ingeleiv Løken-Amsrud; Kjell-Morten Myhr; Søren Jacob Bakke et al. (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. (external link)
• Ellen Skorve; Astri J. Lundervold; Øivind Torkildsen et al. (2022). Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS – A longitudinal correlation study. (external link)
• Trygve Holmøy; Kristin Ingeleiv Løken-Amsrud; Jacob Bakke et al. (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. (external link)
• Erik Ingmar Hallin; Trond Trætteberg Serkland; Kjell-Morten Myhr et al. (2022). Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. (external link)
• Jakob Rishovd Karlowicz; Mattias Klakegg; Jan Harald Aarseth et al. (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. (external link)
• Kristin Ingeleiv Løken-Amsrud; Trygve Holmøy; Søren J. Bakke et al. (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. (external link)
• Øivind Fredvik Torkildsen; Nina Agnethe Grytten; Kjell-Morten Myhr (2007). Immunomodulatory treatment of multiple sclerosis in Norway. (external link)
• Øivind Torkildsen; Ralf A Linker; Jose Mm Sesmero et al. (2021). Living with secondary progressive multiple sclerosis in Europe: Perspectives of multiple stakeholders. (external link)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. (external link)

Professional article

• Øivind Torkildsen; Trygve Holmøy; Kjell-Morten Myhr (2018). Severe multiple sclerosis reactivation after gonadotropin treatment. (external link)

Conference poster

• Tilde Rasmussen; Marton König; Åslaug Rudjord Lorentzen et al. (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis. (external link)
• Trond Trætteberg Serkland; Erik Ingmar Hallin; Kjell-Morten Myhr et al. (2022). LC-MS/MS quantification of ocrelizumab in the treatment of multiple sclerosis. (external link)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies. (external link)
• Marton König; Asia-Sophia Fumika Michaela Wolf; Anthony Ravussin et al. (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. (external link)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2024). Short-Term and Long-Term Impact of Autologous Haematopoietic Stem Cell Transplantation on Immune Profiles in Relapsing-Remitting Multiple Sclerosis. (external link)

Conference abstract

• Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Anne Marita Milde et al. (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. (external link)
• Nina Agnethe Grytten; Øivind Fredvik Torkildsen; Jan Harald Aarseth et al. (2007). Increasing prevalence of multiple sclerosis in the elderly in western Norway. (external link)
• SS Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. (external link)
• Grytten Nina; Espen Benjaminsen; Elisabeth Gulowsen Celius et al. (2017). Cancer risk in multiple sclerosis. (external link)
• Øivind Torkildsen; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. (external link)
• Stig Wergeland; Øivind Fredvik Torkildsen; Kjell-Morten Myhr et al. (2009). Histopathological characterisation of the cuprizone model for demyelination. (external link)
• Christine Stansberg; S Angelska; Evert-Jan Kooi et al. (2009). Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. (external link)

Doctoral thesis (PhD)

• Øivind Fredvik Torkildsen (2010). Environmental risk factors for multiple sclerosis. Results from animal and human studies on diet, vitamin D and Epstein-Barr virus. (external link)

Conference lecture

• Egil Rørvik Røsjø; Kjell-Morten Myhr; Margitta Theodora Kampman et al. (2015). Vitamin D og interferon-behandling ved multippel sklerose. (external link)
• Trond Trætteberg Serkland; Erik Ingmar Hallin; Kjell-Morten Myhr et al. (2022). Rituximab in the treatment of multiple sclerosis: A pharmacokinetic-pharmacodynamic model. (external link)

Academic literature review

• Kristin Nielsen Varhaug; Øivind Torkildsen; Kjell-Morten Myhr et al. (2019). Neurofilament light chain as a biomarker in multiple sclerosis. (external link)
• Shamundeeswari Anandan; Karina Maciak; Regina Breinbauer et al. (2025). Brain-derived blood biomarkers in multiple sclerosis—current trends and beyond. (external link)
• Silje Agnethe Stokke; Stig Wergeland; Øivind Torkildsen et al. (2013). Neuromyelitis optica. (external link)
• Kjell-Morten Myhr; Øivind Torkildsen; Peter Andreas Vold Lossius et al. (2019). B cell depletion in the treatment of multiple sclerosis. (external link)
• Kjell-Morten Myhr; Nina Grytten; Øivind Torkildsen et al. (2015). The Norwegian Multiple Sclerosis Registry and Biobank. (external link)
• Joost Smolders; Øivind Torkildsen; William Camu et al. (2019). An Update on Vitamin D and Disease Activity in Multiple Sclerosis. (external link)
• Lossius Peter Andreas Vold; Jorunn Johansen; Øivind Torkildsen et al. (2012). Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation. (external link)
• Trygve Holmøy; Rune Alexander Høglund; Zsolt Illes et al. (2020). Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. (external link)
• Nina Grytten; Øivind Torkildsen; Kjell-Morten Myhr (2015). Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. (external link)
• Stig Wergeland; Øivind Torkildsen; Lars Bø et al. (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. (external link)
• Ingrid Anne Lie; Merlin M. Weeda; Rozemarijn M. Mattiesing et al. (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. (external link)
• Karine Eid; Marte-Helene Bjørk; Nils Erik Gilhus et al. (2024). Adverse Childhood Experiences and the Risk of Multiple Sclerosis Development: A Review of Potential Mechanisms. (external link)

Media feature article

• Ingrid Anne Lie; Bjørn Blomberg; Øystein Alexander Power et al. (2018). Mann i 20-årene med svimmelhet, dobbeltsyn og perifer facialisparese. (external link)
• Øivind Torkildsen; Brit Ellen Rød; Lars Bø et al. (2022). Amming og behandling av multippel sklerose. (external link)

Letter to the editor

• Ingrid Anne Lie; Brit Ellen Rød; Silje Agnethe Stokke et al. (2023). Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. (external link)
• Øivind Torkildsen; Jan Harald Aarseth; Elisabeth Gulowsen Celius et al. (2014). Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. (external link)
• Stig Wergeland; Trond Riise; Øivind Torkildsen (2018). Response to 'Seasonal variation of vitamin D and Epstein?Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'. (external link)
• Trygve Holmøy; Kristin Ingeleiv Løken-Amsrud; Margitta Theodora Kampman et al. (2014). Re: Vitamin D-how much is enough, and is more better for your Health?. (external link)
• Gro Owren Nygaard; Hilde Marie Torgauten; Lars Skattebøl et al. (2022). Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. (external link)
• Sreeram V Ramagopalan; Heather EC Hanwell; Gavin Giovannoni et al. (2010). Vitamin D-Dependent Rickets, HIA-DRB1, and the Risk of Multiple Sclerosis. (external link)
• Trygve Holmøy; Øivind Torkildsen (2017). Re: Familieplanlegging, graviditet og amming ved multippel sklerose. (external link)
• Øivind Torkildsen; Kjell-Morten Myhr; Pascal Brügger-Synnes et al. (2024). Antiviral therapy with tenofovir in MS. (external link)
• Nina Grytten; Øivind Torkildsen; Kjell-Morten Myhr (2015). Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'. (external link)

Editorial/Leader article

• Øivind Torkildsen (2025). Multiple Sclerosis, NMOSD, and the Risk of Autoimmune Diseases. (external link)
• Trygve Holmøy; Øivind Torkildsen (2016). Can Vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?. (external link)
• Thomas Skripuletz; Øivind Torkildsen (2023). Editorial: New cerebrospinal fluid research to uncover mechanisms driving neurological and psychiatric diseases, volume II. (external link)

Academic book chapter

• Kjell-Morten Myhr; Øivind Torkildsen; Lars Bø (2014). Multippel Sklerose. (external link)

See a complete overview of publications in Cristin.

Horizon - EBV-MS  - https://www.uib.no/en/ebvms/170748/overview-all-ebv-ms-project-partners

RAM-MS - http://ram-ms.no

OVERLORD-MS - https://www.helse-bergen.no/kliniske-studier/okrelizumab-versus-rituksimab-som-behandling-for-tidlig-attakvis-multippel-sklerose-overlord-ms